1. A high throughput bispecific antibody discovery pipeline.
- Author
-
Segaliny, Aude I., Jayaraman, Jayapriya, Chen, Xiaoming, Chong, Jonathan, Luxon, Ryan, Fung, Audrey, Fu, Qiwei, Jiang, Xianzhi, Rivera, Rodrigo, Ma, Xiaoya, Ren, Ci, Zimak, Jan, Hedde, Per Niklas, Shang, Yonglei, Wu, George, and Zhao, Weian
- Subjects
BISPECIFIC antibodies ,HIGH throughput screening (Drug development) ,MOLECULAR cloning ,T cells - Abstract
Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering for efficient generation of BsAb library cells, followed by functional interrogation at the single-cell level to identify and sort positive clones and downstream sequence identification and functionality characterization. Using a CD19xCD3 bispecific T cell engager (BiTE) as a model, we demonstrate that our single-cell platform possesses a high throughput screening efficiency of up to one and a half million variant library cells per run and can isolate rare functional clones at a low abundance of 0.008%. Using a complex CD19xCD3 BiTE-expressing cell library with approximately 22,300 unique variants comprising combinatorially varied scFvs, connecting linkers and VL/VH orientations, we have identified 98 unique clones, including extremely rare ones (~ 0.001% abundance). We also discovered BiTEs that exhibit novel properties and insights to design variable preferences for functionality. We expect our single-cell platform to not only increase the discovery efficiency of new immunotherapeutics, but also enable identifying generalizable design principles based on an in-depth understanding of the inter-relationships between sequence, structure, and function. A single-cell based bispecific antibody (BsAb) discovery pipeline, based on a microfluidics droplets generation and sorting systems, has the potential to speed up the discovery and development of functional antibodies such as BsAb therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF